Beijing Tongrentang Co Ltd
SSE:600085
Net Margin
Beijing Tongrentang Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Beijing Tongrentang Co Ltd
SSE:600085
|
50.7B CNY |
9%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
783.4B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
389.2B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
233.7B CHF |
20%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.1B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
223.1B USD |
27%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
198.6B CHF |
23%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
13%
|
Beijing Tongrentang Co Ltd
Glance View
Nestled in the heart of Beijing's bustling historic district, Beijing Tongrentang Co. Ltd. trace their origins back to 1669 during the Qing Dynasty. This venerable institution has often been heralded as the steward of traditional Chinese medicine (TCM), expertly bridging over three centuries of heritage with the demands of modern healthcare. The company's deep-rooted ethos is centered on the enduring principles of TCM, which emphasize balance and holistic well-being, a philosophy that they have meticulously preserved and adapted over generations. The intricate potions, herbal remedies, and elaborate tonics they craft are derived from a unique blend of ancient recipes and rigorous quality standards, ensuring both authenticity and efficacy. This reverence for tradition, coupled with a commitment to innovation, underpin the strength and credibility of Tongrentang's brand, allowing it to not only maintain but also expand its standing globally. From the cobblestones of Beijing, Tongrentang's operations today encompass a sophisticated network of production facilities, retail outlets, and strategic partnerships, turning the company into a formidable player in the health sector. While steeped in history, this hallmark of traditional Chinese medicine makes its earnings through a modern business model that includes pharmaceuticals, healthcare services, and retail. Their production capabilities boast advanced manufacturing technologies that complement their traditional processes, ensuring scalable and efficient operations without compromising the character of their products. Retail remains a core avenue, with a vast array of stores in China and abroad that serve as conduits for both commerce and education, introducing new generations to TCM. Additionally, Tongrentang has successfully ventured into healthcare services, with clinics providing wellness treatments and consultations that encapsulate the essence of their medicinal philosophy, thus diversifying income streams while deepening consumer engagement with its storied brand.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Beijing Tongrentang Co Ltd's most recent financial statements, the company has Net Margin of 9.1%.
You don't have any saved screeners yet